Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 September 1998

Role of histamine H3-receptors in the proliferation of neoplastic cells in vitro

Adam Szelˆąg

Med Sci Monit 1998; 4(5): BR747-755 :: ID: 501958

Abstract

The study was devoted to the investigation of the effect of tioperamide and clobenpropit - the antagonists, as well as R-alpha-methylhistamine and imetit - the agonists of histamine H3 receptors on the proliferation of neoplastic cells in vitro. The study was performed upon the following cell lines: BM - human melanoma, A-431 - human cutaneous carcinoma, TT - human medullary thyroid carcinoma, Ta3Hauszka - mammary cancer of mice, F6B¸Y - normal bovine foetal thyroid. For each cell line, test value (TV) and test index (TI) were determined according to generally-used criteria. The study presented in our paper is the first attempt to use the modulation of histamine H3 receptors in the regulation of neoplastic cells proliferation. It was demonstrated that antagonists of histamine H3 receptors - tioperamide and clobenpropit considerably inhibit the proliferation of the cells of human neoplasms - melanoma and cutaneous carcinoma. An opposite effect was observed in the case of the agonists of these receptors - R-alpha-methylhistamine and imetit - which very clearly stimulate proliferation of these neoplastic cells. Non-neoplastic cells of normal bovine thyroid are slightly sensitive to the inhibiting activity of antagonists as well as to proliferation stimulating activity of the agonists of these receptors. The activity of the studied compounds may be associated with H3 receptors, since the antagonists of these receptors inhibit proliferating action of agonists. These observations suggest that mediators released after the use of the antagonists of these receptors, or intracellular changes taking place as an effect of their action, slow down the proliferation of neoplastic cells, but not normal cells.

Keywords: proliferation of neoplastic cells, H3 receptors

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750